K
Kate J. Newberry
Researcher at University of Texas MD Anderson Cancer Center
Publications - 60
Citations - 3604
Kate J. Newberry is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myelofibrosis & Ruxolitinib. The author has an hindex of 22, co-authored 56 publications receiving 3026 citations. Previous affiliations of Kate J. Newberry include Oregon Health & Science University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang,Simon Rule,Peter Martin,Andre Goy,Rebecca Auer,Brad S. Kahl,Brad S. Kahl,Wojciech Jurczak,Ranjana H. Advani,Jorge E. Romaguera,Michael E. Williams,Jacqueline C. Barrientos,Ewa Chmielowska,John Radford,Stephan Stilgenbauer,Martin Dreyling,Wiesław Wiktor Jędrzejczak,Peter Johnson,Stephen E. Spurgeon,Lei Li,Liang Zhang,Kate J. Newberry,Zhishuo Ou,Nancy Cheng,Bingliang Fang,Jesse McGreivy,Fong Clow,Joseph J. Buggy,Betty Y. Chang,Darrin M. Beaupre,Lori Kunkel,Kristie A. Blum +31 more
TL;DR: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma and is enrolled into two groups: patients who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles.
Journal ArticleDOI
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
Michael Wang,Luis Fayad,Nicolaus A. Wagner-Bartak,Liang Zhang,Fredrick Hagemeister,Sattva S. Neelapu,Felipe Samaniego,Peter McLaughlin,Michelle A. Fanale,Anas Younes,Fernando Cabanillas,Nathan Fowler,Kate J. Newberry,Luhong Sun,Ken H. Young,Richard E. Champlin,Larry W. Kwak,Lei Feng,Maria Badillo,Maria Teresa Bejarano,Kimberly Hartig,Wendy Chen,Yiming Chen,Catriona Byrne,Neda Bell,Jerome B. Zeldis,Jorge E. Romaguera +26 more
TL;DR: Oral lenalidomide plus rituximab is well tolerated and effective for patients with relapsed or refractory MCL and the primary efficacy endpoint was overall response (complete or partial response).
Journal ArticleDOI
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
Michael Wang,Nathan Fowler,Nicolaus A. Wagner-Bartak,Li Feng,Jorge E. Romaguera,Sattva S. Neelapu,Fredrick B. Hagemeister,Michelle A. Fanale,Yasuhiro Oki,Barbara Pro,Jharna N. Shah,Sheeba K. Thomas,Anas Younes,Chitra Hosing,Liang Zhang,Kate J. Newberry,Madhav Desai,N Cheng,Maria Badillo,M Bejarano,Yiming Chen,Ken H. Young,Richard E. Champlin,Larry W. Kwak,Luis Fayad +24 more
TL;DR: Rituximab plus oral lenalidomide is well tolerated and effective for patients with relapsed/refractory DLBCL and TL, and SCT after lenalidOMide–rituximAB is associated with prolonged response duration.
Journal ArticleDOI
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.
Kate J. Newberry,Keyur P. Patel,Lucia Masarova,Rajyalakshmi Luthra,Taghi Manshouri,Elias Jabbour,Prithviraj Bose,Naval Daver,Jorge E. Cortes,Hagop M. Kantarjian,Srdan Verstovsek +10 more
TL;DR: Outcomes after ruxolitinib discontinuation in MF patients enrolled in a phase 1/2 study are described and it is suggested that clonal evolution or decreasing platelet counts while on ruxolinib therapy may be markers of poor prognosis.
Journal ArticleDOI
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
Keyur P. Patel,Kate J. Newberry,Rajyalakshmi Luthra,Elias Jabbour,Sherry Pierce,Jorge E. Cortes,Rajesh R. Singh,Meenakshi Mehrotra,Mark J. Routbort,Madan G. Luthra,Taghi Manshouri,Fabio P.S. Santos,Hagop M. Kantarjian,Srdan Verstovsek +13 more
TL;DR: Target next-generation sequencing of a panel of 28 genes recurrently mutated in hematologic malignancies in a cohort of patients with myelofibrosis found that multigene profiling may be useful for therapeutic planning for MF, and patients with ≥3 mutations had the worst outcomes.